Allogene Therapeutics, Inc., a biotechnology company operating within the health care sector, has been making strides in the development of innovative therapies aimed at treating blood cancers and solid tumors. The company specializes in allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, a cutting-edge approach in cancer treatment that harnesses the power of the immune system to target and destroy cancer cells.

Based in South San Francisco, Allogene Therapeutics primarily serves patients in California, leveraging its strategic location to facilitate research and development activities. The company’s focus on allogeneic CAR-T therapy distinguishes it within the biotechnology industry, as it seeks to address the limitations associated with traditional autologous CAR-T therapies, such as high costs and lengthy production times.

As of October 27, 2025, Allogene Therapeutics’ stock was trading at a close price of $1.26 on the Nasdaq exchange. This figure represents a significant fluctuation over the past year, with the stock reaching a 52-week high of $3.78 on February 18, 2025, and a 52-week low of $0.86 on May 13, 2025. These fluctuations reflect the dynamic nature of the biotechnology sector and the market’s response to the company’s developmental milestones and challenges.

With a market capitalization of approximately $279.57 million, Allogene Therapeutics is positioned as a notable player in the biotechnology landscape. The company’s financial metrics underscore its potential for growth and the market’s interest in its innovative therapeutic approaches.

Allogene Therapeutics continues to advance its research and development efforts, aiming to bring its therapies to market and improve outcomes for patients with blood cancers and solid tumors. For more information about the company’s mission, offerings, and stock trading, interested parties can visit their website at www.allogene.com or follow their activities on the Nasdaq stock exchange.